Medication-Assisted Treatment (MAT) in New Jersey

What MAT means, in plain terms

Medication-assisted treatment (MAT), sometimes now called medications for opioid use disorder (MOUD) when referring specifically to opioids, means treatment with FDA-approved medication, which may be combined with counseling and behavioral support when that fits the individual's plan. Counseling can help many people, but it is not a precondition for receiving medication — whether and when to start a medication, which one, and what support services accompany it are individualized clinical decisions made with a licensed prescriber. According to the National Institute on Drug Abuse, the medications most commonly used for opioid use disorder are methadone, buprenorphine, and naltrexone, and naltrexone is also approved for alcohol use disorder.

A common misconception is that MAT just substitutes one addictive substance for another. Federal research on this is fairly consistent: these medications work differently from the opioids or alcohol someone may have been using, and for methadone and buprenorphine specifically, they reduce cravings and withdrawal without producing the same intensity of euphoria — when taken as prescribed. None of that is a statement about what any individual should take; that decision belongs to a licensed prescriber evaluating a specific person.

The three medications, described neutrally

Methadone is a full opioid agonist, meaning it activates the same receptors as other opioids but in a controlled, measured way when dispensed through a licensed program. Buprenorphine is a partial agonist — it activates those receptors to a lesser degree and can also block other opioids from attaching, which is part of why it's available in office-based settings with fewer restrictions than methadone. Naltrexone is an opioid antagonist — it blocks opioid receptors rather than activating them, and it's also approved for alcohol use disorder because of how it affects the reward pathway involved in cravings.

None of these medications work the same way for every person, and choosing between them (or deciding none is appropriate) is a clinical decision made with a prescriber, based on someone's medical history, other medications, and personal circumstances — not something a general information page can determine.

Suboxone, Sublocade, and Brixadi: buprenorphine by brand name

Many people search for buprenorphine by its brand names. These products all contain buprenorphine, but they are taken in different ways. Which one fits, if any, is a decision for a licensed prescriber.

Suboxone and generic buprenorphine/naloxone

Suboxone is a film that dissolves under the tongue or inside the cheek. It combines buprenorphine with naloxone, which is added to discourage misuse by injection. Generic buprenorphine/naloxone films and tablets are also widely available. These are usually taken daily and picked up at a pharmacy. Starting buprenorphine too soon after other opioids can cause sudden withdrawal, so prescribers plan the first dose carefully — and with fentanyl, that timing can be more complicated.

Sublocade (monthly injection)

Sublocade is an extended-release buprenorphine injection given once a month under the skin. The FDA approved it in 2017 for people who have already started buprenorphine by mouth or under the tongue and been on a stable dose for at least seven days. It must be given by a healthcare provider in a clinical setting; it is not handed to patients to take home.

Brixadi (weekly or monthly injection)

Brixadi is an extended-release buprenorphine injection the FDA approved in 2023. It comes in weekly and monthly versions, which gives prescribers more options for scheduling. According to the FDA, it can be started in people who are already on buprenorphine or after a single test dose of buprenorphine under the tongue. Like Sublocade, it is given by a healthcare provider, not at home.

How the options compare at a glance

• Suboxone / generic films or tablets: buprenorphine taken daily, usually at home, from a pharmacy.
• Sublocade: buprenorphine injection once a month at a provider's office, after a stable start on daily buprenorphine.
• Brixadi: buprenorphine injection weekly or monthly at a provider's office.
• Vivitrol: naltrexone injection once a month; requires a period free of opioids before starting.
• Methadone: dispensed through a certified opioid treatment program, often daily at first.

Injectable versions can mean fewer missed doses and no medication kept at home. Daily films can be easier to adjust. Cost, coverage, and how often someone can get to an office also matter. These are trade-offs to talk through with a prescriber.

Questions to ask about injectable buprenorphine

• Does this prescriber or clinic offer Sublocade, Brixadi, or both?
• What has to happen before the first injection?
• Does my plan require prior authorization, and who submits it?
• Is the medication billed through a pharmacy or the office, and what will I owe?
• What happens if I miss an appointment?

In New Jersey, NJ FamilyCare and many commercial plans cover buprenorphine, but coverage rules differ by product and plan. See NJ FamilyCare coverage for addiction treatment and the guide to paying for detox in New Jersey for questions to ask your plan. If opioid withdrawal needs to be managed first, see opioid and fentanyl detox in New Jersey.

OTPs vs. office-based prescribers

Methadone can only be dispensed through a federally certified opioid treatment program (OTP), which involves daily or near-daily visits, at least initially, and OTPs make counseling and support services available alongside the medication. Buprenorphine can be prescribed by qualified physicians, nurse practitioners, or physician assistants in an office-based setting, which generally means fewer required in-person visits and more flexibility in where care happens, including some primary care and telehealth settings. Naltrexone (oral or the extended-release injectable often referred to by the brand name Vivitrol) is also typically managed by an office-based prescriber.

SAMHSA has expanded flexibility for OTPs in recent years around take-home methadone doses, so it's worth asking a specific program what its current visit schedule looks like rather than assuming a fixed daily requirement — the rules have changed since older descriptions were written.

Common myths worth checking

A few claims come up often enough that they're worth naming directly, not to argue a position but to point toward where the underlying research actually comes from.

• "MAT is just another addiction" — federal research agencies describe these medications as working differently from the substances someone may have been using, particularly regarding euphoria, when taken as prescribed; ask a prescriber to explain the specific medication being considered.
• "MAT means you're not really in recovery" — this is a values-based claim some people and programs hold, but it isn't a clinical or legal standard, and different programs and support communities take different positions on it.
• "You have to stay on it forever" — length of treatment varies by individual and is a decision made between a person and their prescriber over time, not a fixed rule.
• "Any doctor can prescribe methadone" — methadone for addiction treatment specifically requires dispensing through a certified OTP; this is different from methadone prescribed for pain by other providers.

Questions to ask a prescriber or program

Because medication choice, dosing, and duration are all individualized clinical decisions, the right move is to bring these questions to a licensed prescriber rather than expect a general answer here.

• Which medications does this program or prescriber offer, and why might one be recommended over another for a given situation?
• What does the visit schedule look like at the start of treatment, and how does it change over time?
• How is counseling incorporated alongside the medication, and is it required or optional?
• What is the plan if someone wants to eventually taper off the medication — how is that approached?

Access in New Jersey

New Jersey has both OTPs and office-based buprenorphine and naltrexone prescribers across the state, and the state's Division of Mental Health and Addiction Services is a starting point for understanding publicly funded options. Availability, wait times, and whether a specific location accepts a specific insurance plan all vary and change over time, so the most reliable approach is to confirm directly with a program or through SAMHSA's national treatment locator, which allows filtering specifically for MAT and OTP services.

Jersey City Detox Support Services does not prescribe, dispense, or verify insurance for any medication or program. What the phone line can do is talk through what someone is looking for and help identify legitimate, verifiable resources — any specific facility or prescriber should be confirmed directly.